LOS ANGELES, CA – In a significant development offering a desperately needed beacon of hope for patients diagnosed with glioblastoma, one of the most aggressive and intractable brain cancers, a new study led by researchers at Keck Medicine of USC has unveiled a promising combination therapy. This novel approach, which integrates Tumor Treating Fields (TTFields) therapy with immunotherapy and chemotherapy, has demonstrated the potential to substantially extend survival rates, particularly for those with larger, inoperable tumors – a subgroup historically facing the most dire prognoses.
Glioblastoma, a diagnosis that currently offers few effective treatments, carries a grim outlook. According to the National Brain Tumor Society, the average survival for patients diagnosed with this devastating disease is a mere eight months. The sheer difficulty in treating glioblastoma stems from its aggressive nature, its ability to infiltrate brain tissue, and the protective yet often obstructive presence of the blood-brain barrier, which shields the brain from many conventional therapies, including those designed to harness the body’s immune system.
The groundbreaking findings from the Keck Medicine of USC study, published in a leading medical journal, suggest that a meticulously orchestrated combination of therapies may finally be cracking the code. By deploying TTFields therapy – which uses targeted electric waves to disrupt tumor growth and alert the immune system – alongside the immunotherapy drug pembrolizumab and the standard chemotherapy agent temozolomide, researchers observed a remarkable 70% increase in overall survival among patients. This substantial improvement offers a transformative shift in the treatment landscape for a cancer that has long defied effective intervention.
The Desperate Need for New Strategies
For decades, the standard of care for glioblastoma has remained largely unchanged: surgical resection, followed by radiation and chemotherapy (typically temozolomide). While this aggressive multi-modal approach can temporarily slow disease progression, recurrence is almost inevitable, and the median survival figures have stubbornly refused to improve significantly. This grim reality has fueled an urgent, global quest for innovative therapies capable of bypassing the inherent challenges posed by brain tumors.
Immunotherapy, a revolutionary class of treatments that harnesses the body’s own immune system to fight cancer, has transformed the prognosis for many other cancer types, from melanoma to lung cancer. However, its success against glioblastoma has been notably limited. The brain’s unique immune environment, coupled with the blood-brain barrier’s protective mechanisms, often prevents immune cells, specifically T cells, from adequately reaching and attacking glioblastoma cells. Tumors themselves also actively create an immunosuppressive microenvironment, further hindering the immune response. This frustrating lack of efficacy for immunotherapy when used alone against glioblastoma underscored the need for an entirely new strategy – one that could prime the brain’s immune system to overcome these formidable barriers.
A New Chapter: The Genesis of a Combined Approach
The conceptual genesis of this new therapeutic strategy began with a deep understanding of the limitations of existing treatments and a bold hypothesis: what if the immune system could be activated directly within the tumor itself? Dr. David Tran, MD, PhD, chief of neuro-oncology with Keck Medicine, co-director of the USC Brain Tumor Center, and corresponding author of the study, theorized that a localized immune reaction, an approach known as in situ immunization, could be the key to unlocking immunotherapy’s potential in glioblastoma.
Dr. Tran’s hypothesis centered on Tumor Treating Fields (TTFields) therapy. TTFields, delivered via a medical device called Optune (manufactured by Novocure, a funder of this study), work by generating low-intensity, alternating electric fields that are applied directly to the tumor site. These fields operate by disrupting the cellular division processes within rapidly multiplying cancer cells. Specifically, they interfere with the formation of the mitotic spindle, a crucial structure for cell division, by pushing and pulling key intracellular components in continually shifting directions. This mechanical interference makes it difficult for tumor cells to divide and proliferate, effectively halting their growth and often leading to cell death. TTFields are delivered through a set of mesh electrodes strategically positioned on the patient’s scalp, generating fields at a precise frequency and intensity focused on the tumor. Patients typically wear these electrodes for approximately 18 hours a day, a commitment that, while significant, pales in comparison to the potential for extended survival.
While TTFields therapy has been approved for glioblastoma treatment in combination with chemotherapy, its mechanism of action extends beyond mere growth inhibition. Researchers observed that TTFields also possess an intriguing ability to attract more tumor-fighting T cells – a type of white blood cell critical for immune surveillance and attack – into and around the glioblastoma. This crucial insight formed the bedrock of Dr. Tran’s novel approach: if TTFields could draw T cells into the tumor and create an inflammatory environment, then perhaps immunotherapy, designed to supercharge these T cells, could finally have a meaningful impact.
Unveiling the Synergy: The 2-THE-TOP Clinical Trial
The theory was put to the test in the 2-THE-TOP, a Phase 2 clinical trial designed to assess the safety and efficacy of this innovative triple combination therapy. The trial enrolled 31 newly diagnosed glioblastoma patients who had already completed initial chemoradiation therapy. Of these, 26 patients received the full combination of TTFields, chemotherapy (temozolomide), and immunotherapy (pembrolizumab).
The treatment regimen was carefully structured: patients received six to 12 monthly treatments of chemotherapy alongside TTFields for up to 24 months, with the duration determined by their response to treatment. The immunotherapy, pembrolizumab – an immune checkpoint inhibitor (ICI) – was administered every three weeks, commencing with the second dose of chemotherapy, also for up to 24 months. Pembrolizumab works by blocking specific proteins on immune cells (checkpoint proteins), effectively "releasing the brakes" on T cells and enhancing their ability to identify and attack cancer cells.
A particularly high-risk subgroup within the trial consisted of seven patients whose tumors were deemed inoperable due to their location within the brain. These patients, traditionally facing the worst prognosis and fewest treatment options, were a critical focus for assessing the true potential of the therapy.
The results were compelling and, for many in the neuro-oncology community, genuinely surprising. Patients who received the triple combination therapy lived approximately 10 months longer than historical control groups who had previously used TTFields with chemotherapy alone. Even more remarkably, those with large, inoperable tumors – the very patients for whom hope was previously minimal – lived approximately 13 months longer. Furthermore, this subgroup demonstrated a much stronger immune activation compared to patients who underwent surgical removal of their tumors, suggesting a profound interaction between the therapy and the tumor’s bulk.
This counterintuitive finding – that larger, unresected tumors might respond better to immune activation – provides a new avenue for understanding glioblastoma biology. Dr. Tran posited that "when it comes to kick-starting the body’s immune response against the cancer, having a larger tumor may provide more targets for the therapy to work against." This suggests that the presence of more tumor cells, when effectively exposed and presented to the immune system by TTFields, could provide a more robust antigenic stimulus, leading to a stronger, more sustained anti-tumor immune response.
Decoding the Mechanism: How the Triple Threat Works
The success of this combination therapy lies in its elegant synergy, where each component plays a distinct yet complementary role.
1. TTFields: The Immune System’s Beacon and Disruptor
At its core, TTFields therapy performs a dual function. First, it acts as a direct cytotoxic agent, mechanically disrupting the proliferation of glioblastoma cells. This immediate disruption of tumor growth is vital in a rapidly advancing disease. Second, and perhaps more critically in this combination, TTFields appear to act as an "immune primer." By interfering with tumor cells, they likely induce immunogenic cell death, leading to the release of tumor antigens (molecules that the immune system can recognize as foreign). This release, combined with the observed influx of T cells into the tumor microenvironment, transforms the previously "cold" and immunosuppressive glioblastoma into a more "hot" and immunologically responsive tumor. The electric fields themselves may also directly influence immune cell migration and activity.
2. Pembrolizumab: Unleashing the Attack
Once TTFields have drawn T cells into the tumor and created an environment ripe for immune recognition, pembrolizumab steps in. As an immune checkpoint inhibitor, it removes the "brakes" that cancer cells often place on T cells. By blocking PD-1, a protein on T cells that, when bound by its ligand (PD-L1) on cancer cells, inactivates the T cell, pembrolizumab allows the newly recruited and activated T cells to sustain their attack. The study further observed that after TTFields attracted T cells, immunotherapy helped these T cells stay active longer and even facilitated their replacement by "even stronger, more effective tumor-fighting T cells." This suggests a sustained amplification loop, where the initial immune activation by TTFields is continuously bolstered by the ICI.
3. Temozolomide: The Standard Bearer
Chemotherapy with temozolomide, the long-standing cornerstone of glioblastoma treatment, likely contributes to the overall effect by further reducing tumor burden and potentially sensitizing tumor cells to the other therapies. Its inclusion ensures that the multi-pronged assault on the cancer is comprehensive, targeting different vulnerabilities of the tumor cells simultaneously.
Dr. Tran eloquently summarized this intricate interplay: "By using TTFields with immunotherapy, we prime the body to mount an attack on the cancer, which enables the immunotherapy to have a meaningful effect in ways that it could not before. Our findings suggest that TTFields may be the key to unlocking the value of immunotherapy in treating glioblastoma." He further likened the process to a "team sport" where "immunotherapy sends players in to attack the tumor (the offense), while TTFields weaken the tumor’s ability to fight back (the defense). And just like in team sports, the best defense is a good offense."
Official Responses and the Road Ahead
The promising results from the 2-THE-TOP trial have been met with cautious optimism within the scientific community and a renewed sense of urgency to validate these findings on a larger scale. Keck Medicine of USC is actively participating in a multicenter Phase 3 clinical trial, a critical step to definitively confirm the efficacy and safety of this combination therapy. Dr. Tran, whose dedication to researching TTFields spans more than a decade, is chairing the steering committee for this pivotal trial, underscoring the institutional commitment and his deep expertise in the field. Dr. Frances Chow, a neuro-oncologist with USC Norris, serves as the principal investigator for the Keck Medicine study site.
This expansive Phase 3 trial is currently underway, spanning 28 sites across the United States, Europe, and Israel. Its ambitious goal is to enroll over 740 patients by April 2029. Crucially, this larger trial is designed to include a diverse cohort of patients, encompassing those with gross total resection (complete surgical removal), partial resection, or biopsy-only tumors. This comprehensive approach will allow researchers to meticulously assess how the extent of surgical tumor removal influences the immune response and the overall effectiveness of the combination therapy. "Further studies are needed to determine the optimal role of surgery in this setting," noted Dr. Tran, "but these findings may offer hope, particularly for glioblastoma patients who do not have surgery as an option."
The study’s authors from the Keck School of Medicine of USC include Dongjiang Chen, PhD, Son Le, PhD, Harshit Manektalia, Ming Li, PhD, and Adam O’Dell. Collaborators from the University of Florida, Ashley Ghiaseddin, MD, and Maryam Rahman, MD, MS, also contributed significantly to this important work. Transparency in research is paramount, and it’s noted that this study received funding from Novocure, the manufacturer of the Optune device. Dr. Tran has also received honoraria from Novocure for consultant work, and both Dr. Chen and Dr. Tran are inventors on two patent applications related to the reported work.
Implications: A New Dawn for Glioblastoma Patients
The implications of these findings are profound, potentially ushering in a new era of glioblastoma treatment. For patients and their families, who often grapple with a diagnosis that offers little hope, this combination therapy represents a tangible step forward, promising not just extended survival but potentially improved quality of life. The ability to effectively treat larger, inoperable tumors is a particularly significant breakthrough, offering an option where none previously existed.
Beyond glioblastoma, the principles demonstrated in this study – using a physical modality like TTFields to prime the immune system locally, thereby rendering "cold" tumors susceptible to immunotherapy – could have broader implications for other difficult-to-treat cancers. Many solid tumors, like glioblastoma, evade immune detection and response, and this strategy could inspire similar combination approaches in other contexts.
As the Phase 3 trial progresses, the neuro-oncology community will keenly watch for validation of these exciting results. The long-term impact on patient survival, quality of life, and the optimal integration of this triple therapy into the existing standard of care will be critical areas of focus. While challenges remain – including the logistical demands of daily TTFields use and the financial implications of such advanced therapies – the Keck Medicine of USC study has undeniably ignited a powerful new spark of optimism in the relentless fight against glioblastoma. The prospect of "unlocking" immunotherapy’s full potential for this devastating disease represents a monumental stride towards a future where a glioblastoma diagnosis no longer equates to an almost immediate death sentence.
About the Author
